In this webinar hosted by DDW, Curia shares its findings that protein X-ray crystallography is essential to accelerate the design process by providing a level of structural detail unmatched by computational methods.

The first challenge in drug discovery is selecting a biological target and validating it as a ‘druggable’ binding site. The key to this is identifying several potent compounds that can be used in more advanced validating assays. To achieve this go/no-go point, good chemical starting points need to be found and then compounds are optimised for binding.

The speakers will describe how Curia’s team designed a new protein construct that provided the first crystal structure of Artemis, an unproven target blocking DNA-repair in oncology.

The webinar will take place on Tuesday 14 October, 8am PDT / 11am EDT / 4pm BST / 5pm CEST

What you will learn:

  • Why accelerating the design of low nanomolar compounds is essential in target validation
  • Structure-driven SAR process requires excellent structural biology, medicinal and computational integration
  • The value of executing a structure-based strategy to fast-track drug delivery and invention

A Q&A with the speakers will follow the presentation.

Register for free now to secure your place at the webinar!